Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / HGEN - Dosing underway in lenzilumab late-stage study in COVID-19


HGEN - Dosing underway in lenzilumab late-stage study in COVID-19

Humanigen ([[HGEN]] +6.4%) has announced treatment of its first COVID-19 patient with lenzilumab in Phase 3 trial, at MedStar Washington Hospital Center, one of 18 sites in the U.S. approved to enroll eligible patients to study lenzilumab, designed specifically to cytokine storm (harmful inflammation).The primary objective of the trial is to determine if lenzilumab can help hospitalized patients with COVID-19 recover faster.

For further details see:

Dosing underway in lenzilumab late-stage study in COVID-19
Stock Information

Company Name: Humanigen Inc.
Stock Symbol: HGEN
Market: OTC
Website: humanigen.com

Menu

HGEN HGEN Quote HGEN Short HGEN News HGEN Articles HGEN Message Board
Get HGEN Alerts

News, Short Squeeze, Breakout and More Instantly...